Integrated NY-ESO-1 antibody and CD8 + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 40, 2011, Pages 16723-16728

  Yuan, Jianda ^a   Adamow, Matthew ^a   Ginsberg, Brian A ^a   Rasalan, Teresa S ^a   Ritter, Erika ^b   Gallardo, Humilidad F ^a   Xu, Yinyan ^a   Pogoriler, Evelina ^a   Terzulli, Stephanie L ^a   Kuk, Deborah ^a   Panageas, Katherine S ^a   Ritter, Gerd ^b   Sznol, Mario ^c   Halaban, Ruth ^c   Jungbluth, Achim A ^b   Allison, James P ^a   Old, Lloyd J ^a,b   Wolchok, Jedd D ^a,b   Gnjatic, Sacha ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY NY ESO 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IPILIMUMAB; T LYMPHOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNITY; MAJOR CLINICAL STUDY; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 80053648839     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1110814108     Document Type: Article

References (57)

1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175-208.
2. Wang RF, Rosenberg SA (1999) Human tumor antigens for cancer vaccine development. Immunol Rev 170:85-100.
3. Preuss KD, Zwick C, Bormann C, Neumann F, PfreundschuhM(2002) Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 188:43-50. (Pubitemid 35398864)
4. Gnjatic S, et al. (2006) NY-ESO-1: Review of an immunogenic tumor antigen. Adv Cancer Res 95:1-30. (Pubitemid 44088423)
5. Old LJ (2008) Cancer vaccines: An overview. Cancer Immun 8(suppl 1):1.
6. Jäger E, et al. (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97:12198-12203.
7. Yuan J, et al. (2009) Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 9:5.
8. Wolchok JD, et al. (2007) Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 15:2044-2050. (Pubitemid 350011745)
9. Speiser DE, et al. (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739-746. (Pubitemid 40322250)
10. Palucka K, Ueno H, Banchereau J (2011) Recent developments in cancer vaccines. J Immunol 186:1325-1331.
11. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-240.
12. Hunder NN, et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703. (Pubitemid 351860862)
13. Higano CS, et al. (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670-3679.
14. Bendandi M, et al. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5:1171-1177. (Pubitemid 29474422)
15. Kantoff PW, et al. (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099-1105.
16. Jäger E, et al. (2006) Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103:14453-14458. (Pubitemid 44484771)
17. Steele JC, et al. (2011) Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther 18:584-593.
18. Robbins PF, et al. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-924.
19. Chen YT, et al. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914-1918.
20. Jungbluth AA, et al. (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856-860. (Pubitemid 32467376)
21. Barrow C, et al. (2006) Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12:764-771. (Pubitemid 43259856)
22. Velazquez EF, et al. (2007) Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 7:11.
23. Stockert E, et al. (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349-1354. (Pubitemid 28189124)
24. Jäger E, et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265-270. (Pubitemid 28060443)
25. Jäger E, et al. (2000) Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97:4760-4765. (Pubitemid 30238631)
26. Gnjatic S, et al. (2003) Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 100:8862-8867. (Pubitemid 36899189)
27. Davis ID, et al. (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101:10697-10702. (Pubitemid 38955805)
28. Valmori D, et al. (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104:8947-8952. (Pubitemid 47175417)
29. Karbach J, et al. (2010) Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 126:909-918.
30. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465.
31. Brunner MC, et al. (1999) CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 162:5813-5820. (Pubitemid 29314933)
32. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA (1996) CTLA-4: A negative regulator of autoimmune disease. J Exp Med 184:783-788. (Pubitemid 26324135)
33. Hodi FS, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723.
34. Weber JS, et al. (2008) Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:5950-5956.
35. Weber J, et al. (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591-5598.
36. Wolchok JD, et al. (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155-164.
37. Robert C, et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526.
38. Hodi FS, et al. (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105:3005-3010. (Pubitemid 351723658)
39. Fong L, et al. (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69:609-615.
40. Yuan J, et al. (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105:20410-20415.
41. Goff SL, Robbins PF, El-Gamil M, Rosenberg SA (2009) No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma. J Immunother 32:884-885.
42. Adams S, et al. (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181:776-784.
43. Yuan J, et al. (2011) CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: Three cases. Cancer Immunol Immunother 60:1137-1146.
44. Fourcade J, et al. (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182:5240-5249.
45. Matsuzaki J, et al. (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 107:7875-7880.
46. Fourcade J, et al. (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207:2175-2186.
47. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174.
48. Nagata Y, et al. (2002) Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci USA 99:10629-10634.
49. Zeng G, et al. (2006) Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 177:3582-3589. (Pubitemid 44359889)
50. Gnjatic S, et al. (2010) NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. Int J Cancer 127:381-393.
51. Tsuji T, et al. (2011) Split T cell tolerance against a self/tumor antigen: Spontaneous CD4 but not CD8 T cell responses against p53 in cancer patients and healthy donors. PLoS ONE 6:e23651.
52. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360. (Pubitemid 38680426)
53. Yuan J, et al. (2010) Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 10:1.
54. Mitsui J, et al. (2010) Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16:2781-2791.
55. Cohen AD, et al. (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5:e10436.
56. Gnjatic S, Old LJ, Chen YT (2009) Autoantibodies against cancer antigens. Methods Mol Biol 520:11-19.
57. Lin Y, et al. (2009) Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 11:912-922.